Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. QIAGEN N.V.
  6. Summary
    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
53.49(c) 54.15(c) 54.34(c) 54.7(c) 54.83(c) Last
891 469 1 162 936 1 570 144 729 348 438 833 Volume
-0.39% +1.23% +0.35% +0.66% +0.24% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2 151 M - -
Net income 2021 450 M - -
Net Debt 2021 923 M - -
P/E ratio 2021 27,8x
Yield 2021 -
Sales 2022 2 043 M - -
Net income 2022 395 M - -
Net Debt 2022 562 M - -
P/E ratio 2022 32,9x
Yield 2022 -
Capitalization 12 443 M 12 443 M -
EV / Sales 2021 6,21x
EV / Sales 2022 6,37x
Nbr of Employees 5 900
Free-Float 98,3%
More Financials
Company
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or... 
Sector
Biotechnology & Medical Research
Calendar
09/22 | 03:00amPresentation
More about the company
Ratings of QIAGEN N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about QIAGEN N.V.
02:22aQIAGEN N : Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/..
PU
09/21DGAP-CMS : QIAGEN N.V.: Release of a capital market information
DJ
09/20QIAGEN NV : DZ Bank reaffirms its Neutral rating
MD
09/17QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German Securitie..
DJ
09/17QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German Securitie..
EQ
09/14QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German Securitie..
DJ
09/14QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German Securitie..
EQ
09/14QIAGEN N.V. : Release of a capital market information
DJ
09/10QIAGEN N : 3M, Qiagen to comply with Biden's COVID-19 vaccination, test mandate
RE
09/10QIAGEN N : supports White House COVID-19 vaccination, test mandate
RE
09/07QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German Securitie..
EQ
09/07QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German Securitie..
DJ
09/07QIAGEN N.V. : Release of a capital market information
DJ
09/06GLOBAL MARKETS LIVE : Puma, Boeing, Holcim, Revolut, Amazon...
09/05Airbus, Nine Others to Join Germany's DAX Index
MT
More news
News in other languages on QIAGEN N.V.
09/217 ERKENNTNISSE über die DAX-Aufsichtsräte
09/21DGAP-CMS : QIAGEN N.V.: Veröffentlichung einer Kapitalmarktinformation
09/20MÄRKTE EUROPA/Evergrande-Krise löst Kursrutsch aus
09/20FRANKFURT STOCK EXCHANGE : Le Dax trébuche pour sa première séance à 40 valeurs
09/20XETRA-SCHLUSS/Neuer DAX mit Startproblemen - Evergrande verdirbt Stimmung
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Chart QIAGEN N.V.
Duration : Period :
QIAGEN N.V. Technical Analysis Chart | QGEN | NL0012169213 | MarketScreener
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 54,83 $
Average target price 56,13 $
Spread / Average Target 2,36%
EPS Revisions
Managers and Directors
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Chief Financial Officer & Managing Director
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
QIAGEN N.V.3.75%12 443
MODERNA, INC.315.47%175 199
LONZA GROUP AG33.09%60 866
IQVIA HOLDINGS INC.43.03%49 103
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-5.78%30 021